Exec-Edge – Page 66 – ExecEdge

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

By Exec Edge Editorial Staff SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes. SAB-185 demonstrated benefit in...

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

By Exec Edge Editorial Staff FullBeauty will acquire plus-size fashion authority ELOQUII Inc. from Walmart, it said in a statement. The acquisition will allow FullBeauty to expand its presence in the $81 billion women’s plus-sized sector in the U.S. ELOQUII...

Input your search keywords and press Enter.